findmyKOL

Massimo Cristofanilli, MD

Enriched profile

Professor of Medicine; Director of Breast Medical Oncology, Division of Hematology and Medical Oncology; Associate Director of Precision Oncology, Sandra and Edward Meyer Cancer Center; Scientific Director, Englander Institute for Precision Medicine · Weill Cornell Medicine

ORCIDNPI
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyHematology / OncologyFocusCancer Cells and Metastasis+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Massimo Cristofanilli is Professor of Medicine; Director of Breast Medical Oncology, Division of Hematology and Medical Oncology; Associate Director of Precision Oncology, Sandra and Edward Meyer Cancer Center; Scientific Director, Englander Institute for Precision Medicine at Weill Cornell Medicine. OpenAlex indexes 1,440 publications with 58,293 citations (h-index 112); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Massimo Cristofanilli, M.D., is Professor of Medicine at Weill Cornell Medicine (Weill Cornell Medical College), Cornell University -- New York, NY; attending physician, NewYork-Presbyterian Hospital. The public record shows 1,440 publications with 58,293 citations (h-index 112), centered on Cancer Cells and Metastasis, Cancer Genomics and Diagnostics, Advanced Breast Cancer Therapies. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 19 companies.

  • Most recent indexed publication: 2026 · Journal of clinical oncology
  • Top research focus: Cancer Cells and Metastasis
  • 9 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 19 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer9 trialsBreast Neoplasms, Male2 trials

Research focus

OpenAlex concept fingerprint
Cancer Cells and MetastasisCancer Genomics and DiagnosticsAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesCancer Research and Treatments

Drugs & molecules

across trials, industry payments and publications
Ibrancegeneric · PalbociclibClinical trials1Industry payments24Publications12Enhertugeneric · TrastuzumabClinical trials1Industry payments1Publications3Keytrudageneric · PembrolizumabClinical trials2Industry payments14Publications

Works with

trial sponsors and companies reporting payments
AstraZeneca UK LimitedClinical trialsIndustry payments27Pfizer Inc.Clinical trialsIndustry payments21Merck Sharp & Dohme LLCClinical trialsIndustry payments20

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,440publications

Distinct works indexed by OpenAlex, matched via ORCID; 25 in PubMed.

58,293citations

Total citations across indexed works.

112h-index

Hirsch index (OpenAlex). i10-index 436.

Clinical & industry

trials, payments and federal funding
9clinical trials

Investigator role on registered studies.

View trials
19companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    100%
    Aromatase Inhibitor100%
    Anastrozole100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/massimo-cristofanilli-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/massimo-cristofanilli-md-facp-76a56115

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    vivo.weill.cornell.edu/display/cwid-mac9795

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu
2 more verified accounts behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    weillcornell.org/massimo-cristofanilli-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • Other

    weillcornell.org/news/podcast-liquid-biopsy-%E2%80%93-cancer%E2%80%99s-clues-in-the-blood

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • Spotify

    open.spotify.com/episode/6U9rw6Vg547PieVdOSdG75

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com
4 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Director of Breast Medical Oncology

    Division of Hematology and Medical Oncology, Weill Cornell Medicine

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.weill.cornell.edu
  • Associate Director of Precision Oncology

    Sandra and Edward Meyer Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
  • Co-leader

    Meyer Cancer Center Breast Cancer Disease Management Team

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →weillcornell.org
1 more role behind the reveal.Reveal →

Awards & honors

honors on the public record
6 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
7 more affiliations behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.